<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105010</url>
  </required_header>
  <id_info>
    <org_study_id>DZ2019J0005</org_study_id>
    <nct_id>NCT04105010</nct_id>
  </id_info>
  <brief_title>Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)</brief_title>
  <official_title>A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dizal (Jiangsu) Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dizal (Jiangsu) Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, non-randomized, open-label, Phase 1/2 clinical study to
      evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in
      patients with peripheral T cell lymphoma, who have progressed on or are
      refractory/intolerable to standard systemic treatment.

      Around 20~40 patients will be subsequently enrolled into 2 different dose cohorts. Additional
      patients may be further enrolled into expansion dose cohorts if efficacy signal is observed
      with good tolerability in the first 20~40 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>From first dose until 28 days after last dose</time_frame>
    <description>To evaluate the safety and tolerability of AZD4205 in patients with peripheral T cell lymphoma (PTCL) at different dose levels in terms of adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Per Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: ORR is the percentage of patients with at least 1 visit response of Complete Response (CR) or Partial Response (PR), prior to progression or further anti-cancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of AZD4205</measure>
    <time_frame>1,8,15, 21 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of AZD4205</measure>
    <time_frame>1,8,15, 21 days after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Open label AZD4205 dose A, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: Open label AZD4205 dose B, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4205</intervention_name>
    <description>AZD4205 will be administrated orally as capsules. AZD4205 treatment will be continued until disease progression or intolerable adverse reactions</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Obtained written informed consent

          2. Patients must have histologically confirmed peripheral T-cell lymphoma according to
             the 2016 revision of the World Health Organization classiÔ¨Åcation of lymphoid neoplasms
             (Swerdlow SH et al, 2016).

          3. Patients must have measurable disease according to the 2014 Lugano classification.

          4. Patients must have progressed on or are refractory to standard systemic therapy, or
             patients were intolerable to standard systemic therapy.

          5. Adequate bone marrow reserve and organ system functions.

        Exclusion Criteria:

          1. Any unsolved toxicity &gt; Common Terminology Criteria for Adverse Events (CTCAE) grade 1
             from previous anti-cancer therapy (except alopecia).

          2. Active infections, active or latent tuberculosis.

          3. Patients with severely decreased lung function.

          4. History of heart failure or QT interval prolongation.

          5. Central nervous system (CNS) or leptomeningeal lymphoma.

          6. History of treatment with Janus kinase (JAK) or signal transducer and activator of
             transcription 3 (STAT3) inhibitor.

          7. Patient has undergone an allogeneic stem cell transplant. Patient had autologous stem
             cell transplant within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Li, MD</last_name>
    <phone>862161097868</phone>
    <email>jason.li@dizalpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Yang, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06133</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

